3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Status
Withdrawn
1
Completed
1
Sponsor Class
OTHER
2
Study Type
Interventional
2
Sponsor
Cancer Type
Breast
6
CNS
2
Other solid neoplasm
1
Conditions
Brain Neoplasms
2
Meningeal Neoplasms
1
Breast Neoplasms
1
Interventions
Temozolomide
400
Radiotherapy
239
Bevacizumab
185
Magnetic Resonance Spectroscopy
168
Radiosurgery
142
Cyclophosphamide
95
Irinotecan
79
Carboplatin
79
Etoposide
78
Radiation
76
pembrolizumab
70
Nivolumab
59
Surgical Procedures, Operative
57
Filgrastim
56
Specimen Handling
53
Cisplatin
50
Blood Specimen Collection
46
Topotecan
45
Vincristine
43
Melphalan
38
Radiotherapy, Intensity-Modulated
36
Pemetrexed
36
Ipilimumab
36
Lomustine
35
Everolimus
35
Magnetic Resonance Imaging
34
Erlotinib Hydrochloride
34
Drug Therapy
34
Surveys and Questionnaires
33
sargramostim
30
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
OTHER
×
patritumab deruxtecan
×
CNS
×
Clear all
NCT05865990
2026-05-04
TUXEDO-3
MedSIR
Phase 2
Completed
63 enrolled
NCT05620914
2025-06-15
PARAMETer
Duke University
Phase 2
Withdrawn